jeudi 3 décembre 2020


TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant

Par Rédaction , dans Communiqués , le 22 novembre 2020

Tuesday, November 17th 2020 at 1:00pm UTC

IDE Approval Clears Path to U.S. Clinical Trial Launch for Vascular Sealant

PARIS–(BUSINESS WIRE)– TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant.

The approval is the most recent validation of TISSIUM’s efforts to develop a unique platform of proprietary polymers, activation technologies, and delivery devices, with applications in multiple therapeutic areas.

TISSIUM’s vascular sealant is designed to address the issue of quickly achieving hemostasis and preventing post-operative bleeding following peripheral vascular surgeries, while also offering biocompatibility and a simple preparation and application process for surgeons. In this application, the configuration of TISSIUM’s polymer complements sutures as a sealant for a fully effective surgical closure.

“We are pleased to receive this approval from the FDA as it represents a key milestone that accelerates the development of our vascular indication and triggers the further expansion of our broad platform,” said Christophe Bancel, CEO of TISSIUM. “We will continue to execute on our strategy to build devices using our core polymer technology and offer applications across multiple therapeutic areas, such as peripheral nerve and hernia repair where we have recently started development.”

The TISSIUM platform leverages proprietary technology, initially developed at the Massachusetts Institute of Technology (MIT) & Brigham and Women’s Hospital, Harvard Medical School, that serves as the foundation of a family of fully synthetic, biomorphic and programmable polymers. These polymers are designed to be used inside the body as sealants, adhesives, barriers, plugs or as a vehicle for drug delivery, as well as implantable devices created outside of the body using 3D printing technology.

With the approval of the IDE, TISSIUM will continue expanding the existing platform, leveraging its internal innovation and design team and forging development partnerships to build the stable of devices on its platform.

About TISSIUM:

TISSIUM is a privately-owned medtech company based in Paris, France that is dedicated to the rapid development and commercialization of a unique biopolymer platform to address various unmet clinical needs.

The company’s platform is based on a proprietary polymer family with unique properties including the ability to conform to and integrate with surrounding tissue to enable tissue reconstruction. Furthermore, the polymer building blocks enable customization to match tissue-specific requirements for different therapeutic areas. The company is developing a portfolio of solutions for peripheral nerve, gastrointestinal, ENT and cardiovascular applications. The company also develops delivery and activation devices for enhanced performance and usability of its family of polymers.

TISSIUM’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013. For more information, please visit: www.TISSIUM.com and @TISSIUMtech.

Contacts

PRESS CONTACTS

Europe

Brice Epry – Chief of Staf

Tel: +33 1 76 21 72 28

contact@TISSIUM.com

Twitter: @TISSIUMtech

U.S.

Marion Janic

mjanic@rooneyco.com

Source: TISSIUM

Étiquettes : , , , , , , , , ,